Related Experiment Video
Updated: Jul 24, 2025
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.4K
Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review
Paolo Strati1, Tara Gregory2,3, Navneet S Majhail4,5
1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
JCO Oncology Practice
|July 5, 2023
Summary
Chimeric antigen receptor T-cell (CAR-T) therapy offers a new way to treat blood cancers. This review covers CAR-T therapy"s clinical use, access, and side effects in adult patients.
Area of Science:
- Oncology
- Immunotherapy
- Cellular Therapy
Background:
- Chimeric antigen receptor T-cell (CAR-T) therapy is an established treatment for hematologic malignancies.
- The field is rapidly evolving with newer CAR-T constructs designed for enhanced efficacy and reduced toxicity.
Approach:
- This review focuses on the clinical application of CAR-T therapies in adult patients with hematologic malignancies.
- It addresses key aspects including patient access, outpatient administration, and referral timing to CAR-T centers.
Key Points:
- FDA-approved CAR-T products target CD19 for B-cell leukemias/lymphomas and BCMA for multiple myeloma.
- Cytokine release syndrome and ICANS are recognized class-specific toxicities.
- Optimal patient selection and management are crucial for successful CAR-T therapy.
Conclusions:
- CAR-T therapy represents a significant advancement in treating blood cancers.
- Understanding access, administration, and toxicity is vital for effective clinical implementation and patient care.
